-
Hospital pharmacies might expect a new antibiotic, dalbavancin, to be available soon, since the FDA sent Pfizer Inc. an approvable letter in late December 2007.
-
-
Hospital pharmacy directors will have another year of anticipating slow budget growth in drug costs due to the ongoing health care industry trends of focusing on reducing drug utilization, increasing generics, and the slowdown in new drug approvals by the FDA, drug budget experts say.
-
Drug Name
Rivastigmine (Exelon®) transdermal patch and oral capsule
-
In a series of 354 elderly breast cancer patients treated with conservative surgery and tamoxifen but without axillary dissection or radiotherapy followed for 15 years, the cumulative incidence of developing axillary disease was 4.2%, and of developing local recurrence was 8.3%. Of the 354 subjects, 268 had died over the 15-year period, 17% of breast cancer and (83%) from causes other than breast cancer.
-
The prognostic importance of cytogenetics was evaluated in 200 adults between 15 and 65 years of age treated on a single ALL cooperative group protocol. Among the 140 having evaluable cytogenetic data, four risk categories were devised. Philadelphia chromosome positive t(9;22), unfavorable (monosomy 7, trisomy 8 or an 11q23 rearrangement), miscellaneous and normal. Overall survival of the miscellaneous group was similar to the normal karyotype patients whereas survival was considerably worse for both unfavorable and Ph + cytogenetic groups. The traditional adverse risk factors of older age and higher presenting white blood cell count were not associated with worse survival after adjusting for cytogenetics. In adult ALL, cytogenetics categories may be the strongest factor in predicting outcome.
-
-
Does erythropoietin worsen cancer death rates? Most hypothyroid patients can be replaced with levothyroxine alone without additional T3. Does aggressive control in type 2 diabetes save lives?
-
-
In a prospective randomized trial comparing post-surgical follow-up for patients with Stage III and IV colon cancer, PET-CT was found to detect recurrence earlier and to result in a greater number of patients eligible for surgical resection of isolated metastases when compared to conventional follow-up schedules that include CT scanning.
